Actuate Therapeutics, Inc. has announced a significant move to enhance its capital base by filing a registration statement for the sale of 30,985,900 shares of common stock and 15,492,950 warrants. This offering, detailed in its recent SEC filing, aims to support the development of its lead cancer treatment, elraglusib, which is currently in clinical trials.

The offering price is set at $0.71 per two shares of common stock, accompanied by a purchase warrant, which allows investors to buy additional shares at an exercise price of $0.45 each. The company anticipates that the proceeds from this offering will be crucial for advancing its clinical programs, particularly for elraglusib, which targets high-impact cancers.

Background

Actuate Therapeutics, Inc., incorporated in Delaware, operates in the pharmaceutical preparations sector (SIC 2834). The company is listed on the Nasdaq under the ticker symbol ACTU. As a clinical-stage biopharmaceutical firm, Actuate focuses on developing therapies for difficult-to-treat cancers through innovative mechanisms, particularly the inhibition of glycogen synthase kinase-3 (GSK-3).

The company has been active in filing various forms with the SEC, including recent submissions such as an S-1/A and a 10-Q. This latest registration statement, filed on October 28, 2026, is part of Actuate's ongoing efforts to secure funding for its clinical initiatives.

What the Filing Says

The filing indicates, "We are selling 30,985,900 shares of our common stock and 15,492,950 warrants to purchase 15,492,950 shares of our common stock." The offering is designed to provide immediate capital to support the company's ongoing clinical studies.

Impact

This capital raise could significantly impact investors and stakeholders in Actuate Therapeutics, particularly those interested in the development of elraglusib. The funding is expected to facilitate further clinical trials, which may lead to new treatment options for patients with various types of cancer. Additionally, the offering may influence other companies in the pharmaceutical preparations sector as they assess their own funding strategies amidst similar challenges.

What's Next

The filing does not specify what happens next, but it is anticipated that the company will proceed with the offering and utilize the funds for its clinical development plans. Investors and analysts will be closely monitoring the progress of Actuate's clinical trials and the potential impact of this funding on the company's future.